- Trials with a EudraCT protocol (74)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
74 result(s) found for: Neoplasms AND Mantle Cell Lymphoma.
Displaying page 1 of 4.
| EudraCT Number: 2016-000548-33 | Sponsor Protocol Number: LyMa101 | Start Date*: 2016-07-20 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011433-27 | Sponsor Protocol Number: ML22489 | Start Date*: 2009-11-04 | |||||||||||
| Sponsor Name:Roche Romania SRL | |||||||||||||
| Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: RO (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003893-17 | Sponsor Protocol Number: SAKK36/13 | Start Date*: 2017-11-23 | ||||||||||||||||
| Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research | ||||||||||||||||||
| Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial | ||||||||||||||||||
| Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-005439-41 | Sponsor Protocol Number: PLRG-10/ML29157 | Start Date*: 2017-08-13 | |||||||||||
| Sponsor Name:Polish Lymphoma Research Group (PLRG) | |||||||||||||
| Full Title: EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE C... | |||||||||||||
| Medical condition: Molecular relapse after the first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma (MCL) patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001557-85 | Sponsor Protocol Number: 5.0 | Start Date*: 2011-08-22 | |||||||||||
| Sponsor Name:Nordic Lymphoma Group | |||||||||||||
| Full Title: NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial | |||||||||||||
| Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Temporarily Halted) DK (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004910-37 | Sponsor Protocol Number: OASIS-II | Start Date*: 2021-05-11 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma | |||||||||||||
| Medical condition: Untreated mantle cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004039-30 | Sponsor Protocol Number: MCL5(MARiT) | Start Date*: 2012-04-03 | |||||||||||
| Sponsor Name:PLymouth Hospitals NHS Trust | |||||||||||||
| Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-000711-88 | Sponsor Protocol Number: PCI-32765MCL2001 | Start Date*: 2012-09-13 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progres... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) BE (Completed) GB (Completed) PL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000413-36 | Sponsor Protocol Number: BGB-3111-306 | Start Date*: 2020-02-24 | |||||||||||
| Sponsor Name:BeiGene, Ltd. | |||||||||||||
| Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Wh... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000540-25 | Sponsor Protocol Number: FIL_KLIMT | Start Date*: 2019-06-25 | |||||||||||
| Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
| Full Title: Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study | |||||||||||||
| Medical condition: BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003465-33 | Sponsor Protocol Number: PLRG12 | Start Date*: 2019-04-24 | ||||||||||||||||
| Sponsor Name:Polish Lymphoma Research Group - PLRG | ||||||||||||||||||
| Full Title: Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT). | ||||||||||||||||||
| Medical condition: Mantle Cell Lymmphoma (MCL) Chronic Lymphocytic Leukaemia (CLL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-004644-70 | Sponsor Protocol Number: | Start Date*: 2010-11-22 | |||||||||||
| Sponsor Name:GOELAMS | |||||||||||||
| Full Title: Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âg... | |||||||||||||
| Medical condition: Traitement d'entretien de patients porteur d'un lymphome du manteau en réponse. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003235-29 | Sponsor Protocol Number: CC-99282-NHL-001 | Start Date*: 2022-01-19 | |||||||||||||||||||||||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||||||||||||||||||||||
| Full Title: A PHASE I/II, MULTI-CENTER, OPENLABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF AN ORALLY AVAILABLE SMALL MOLECULE, CC-99282, ALONE AND IN COMBINATION WITH ANTILYMPH... | |||||||||||||||||||||||||||||||||
| Medical condition: Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central ner... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) AT (Prematurely Ended) BE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004553-72 | Sponsor Protocol Number: J2N-OX-JZNM(LOXO-BTK-20019) | Start Date*: 2021-07-14 | |||||||||||
| Sponsor Name:Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
| Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) | |||||||||||||
| Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Completed) FR (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) HU (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-004225-24 | Sponsor Protocol Number: PCI-32765CAN3001 | Start Date*: 2013-01-15 | ||||||||||||||||||||||||||
| Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
| Full Title: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | ||||||||||||||||||||||||||||
| Medical condition: chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SE (Completed) BE (Trial now transitioned) IE (Completed) PT (Trial now transitioned) HU (Completed) NL (Ongoing) GR (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-001363-12 | Sponsor Protocol Number: TRIANGLE | Start Date*: 2016-03-24 | |||||||||||||||||||||
| Sponsor Name:Klinikum der Universität München, Medizinische Klinik und Poliklinik III | |||||||||||||||||||||||
| Full Title: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial | |||||||||||||||||||||||
| Medical condition: Generalized mantle cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-002625-38 | Sponsor Protocol Number: ADCT-402-103 | Start Date*: 2018-12-11 | ||||||||||||||||
| Sponsor Name:ADC Therapeutics SA | ||||||||||||||||||
| Full Title: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3) | ||||||||||||||||||
| Medical condition: Diffuse large B-Cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-001547-25 | Sponsor Protocol Number: ZILO-301 | Start Date*: 2023-04-04 | |||||||||||||||||||||
| Sponsor Name:Oncternal Therapeutics, Inc | |||||||||||||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma... | |||||||||||||||||||||||
| Medical condition: Relapsed or Refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2012-002542-20 | Sponsor Protocol Number: MCLR2elderly | Start Date*: 2013-05-21 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab al... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) DE (Ongoing) NL (Ongoing) PT (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003148-19 | Sponsor Protocol Number: INCB50465-205 | Start Date*: 2018-05-15 | |||||||||||
| Sponsor Name:Incyte Corporation | |||||||||||||
| Full Title: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor. | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
